U.S., Jan. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07311941) titled 'Rapid Escalation of LipiD Lowering Therapy to Reduce RecUrrent Cardiovascular Event' on Dec. 17, 2025.
Brief Summary: Hyperlipidaemia especially elevation of low-density lipoprotein cholesterol (LDL-C) is known to be the main contributor to the development of atherosclerotic cardiovascular disease (ASCVD).
Lowering LDL-C have been shown to reduce the risk of ASCVD2,3. Both the American Heart Association (AHA) and the European Society of Cardiology (ESC) advocated aggressive LDL-C target with statin being the first-line lipid-lowering therapy (LLT). However, a significant portion of patients did not attain their LDL-C goal in our loc...